| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 02/09/2006 | US20060029656 Replacement enzyme cochleates |
| 02/09/2006 | US20060029655 Method for preparation of vesicles loaded with biological material and different uses thereof |
| 02/09/2006 | US20060029654 Analgesic patch for sports injury rehabilitation medicine and method to alleviate pain |
| 02/09/2006 | US20060029650 Combination SIS and vacuum bandage and method |
| 02/09/2006 | US20060029649 Stabilized antimicrobial agents |
| 02/09/2006 | US20060029648 Stimulant/desensitizer swabs |
| 02/09/2006 | US20060029644 In vitro biochemical reactions with free anhydrous D-ribose |
| 02/09/2006 | US20060029635 Growth hormone formulations |
| 02/09/2006 | US20060029628 Use of a volatile cooling sensate on fibrous tissues to provide a sensation of rhinological decongestion |
| 02/09/2006 | US20060029627 Antipruritic composition and wound-healing-promoting composition |
| 02/09/2006 | US20060029623 Invert emulsions comprising at least one active agent sensitive to water and cosmetic/dermatological applications thereof |
| 02/09/2006 | US20060029622 Water in oil emulsion comprising sterolesters |
| 02/09/2006 | US20060029611 Prevention and treatment of amyloidogenic disease |
| 02/09/2006 | US20060029599 Lyophilizing an aqueous formulation comprising a high concentration, 50 mg/ml or more of an immunoglobulin IgG antibody, in particular, daclizumab, in 5-25 mM histidine buffer, having pH 5.5-6.5, 0.005%-0.03% polysorbate, and sucrose |
| 02/09/2006 | US20060029592 Methods of treating peripheral arterial occlusions |
| 02/09/2006 | US20060029571 Hyaluronan is combined with a polyglycol, such as polyethylene glycol; preparations may maintain their viscosity and lubricity for extended time periods (e.g., 2 years) without requiring refrigeration or special storage conditions |
| 02/09/2006 | US20060029569 Water-in-oil emulsions with anionic groups, compositions, and methods |
| 02/09/2006 | US20060029556 Aqueous-alcoholic depigmenting gels |
| 02/09/2006 | US20060029552 Carrier particles for use in dry powder inhalers |
| 02/09/2006 | US20060029551 Stable particle formulations of erythropoietin receptor agonists |
| 02/09/2006 | DE102005004219A1 Preparation of homeopathic agent, useful e.g. hair growth agent (e.g. for eye brows) and as skin cleaning agent, comprises replacing medicament with carrier substance having certain ratio with medicament having altered ratio |
| 02/09/2006 | DE102004032322A1 Propellant-containing aerosol suspension useful for treating diseases e.g. asthma, pain contains active substance with chemically bound water, propellant gas or its mixture |
| 02/09/2006 | DE102004031668A1 Produkte zur Reinigung der Intimregion Products for cleaning the genital region |
| 02/09/2006 | CA2638747A1 Combination drug therapy for reducing scar tissue formation |
| 02/09/2006 | CA2618720A1 Clathrate of chlorine dioxide |
| 02/09/2006 | CA2576087A1 Polymeric adhesive matrix with salified carboxylic groups for transdermal use |
| 02/09/2006 | CA2576031A1 A multiple emulsion excipient for cosmetic actives |
| 02/09/2006 | CA2575933A1 Stabilised prostaglandin composition |
| 02/09/2006 | CA2575906A1 Compositions forming non-lamellar dispersions |
| 02/09/2006 | CA2575695A1 Vascular tunneler |
| 02/09/2006 | CA2575555A1 A gastric retained dosage form of gabapentin |
| 02/09/2006 | CA2575330A1 Compositions and methods for nutrition supplementation |
| 02/09/2006 | CA2574958A1 Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation |
| 02/09/2006 | CA2574925A1 Pharmaceutical dosage forms including rasagiline |
| 02/09/2006 | CA2574741A1 Methods for prevention and treatment of mastitis |
| 02/09/2006 | CA2574583A1 Methods of use of herbal compositions |
| 02/09/2006 | CA2574555A1 Phenytoin formulations, and uses thereof in wound healing |
| 02/09/2006 | CA2574303A1 Modafinil oral lyophilizate |
| 02/09/2006 | CA2573892A1 Implantable device having reservoir with controlled release of medication and method of manufacturing the same |
| 02/09/2006 | CA2572919A1 Delivery system |
| 02/09/2006 | CA2572292A1 Tablet for pulsed delivery |
| 02/09/2006 | CA2571621A1 Gilsonite derived pharmaceutical delivery compositions and methods : cosmetic and nail applications |
| 02/08/2006 | EP1623757A1 Microcapsules (XXXII) |
| 02/08/2006 | EP1623722A1 Composition for ophthalmic use |
| 02/08/2006 | EP1623711A1 External patch containing estrogen and/or progestogen |
| 02/08/2006 | EP1623703A1 Controlled release hydrocodone formulations |
| 02/08/2006 | EP1623065A2 Method for making antimicrobial polyester-containing articles with improved wash durability and articles made thereby |
| 02/08/2006 | EP1623021A1 Method for storing tumor cells |
| 02/08/2006 | EP1622808A1 Fluidization of particles for encapsulation in oral dosage pharmaceutical products |
| 02/08/2006 | EP1622657A2 Dialysis valve and method |
| 02/08/2006 | EP1622629A2 Controlled release composition containing a strontium salt |
| 02/08/2006 | EP1622625A1 Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo [5.2.o] non-1 (7)-en-2-yl )alkyl] phosphonic acid and derivatives and methods of use thereof |
| 02/08/2006 | EP1622617A2 New pharmaceutical compositions based on anticholinergics and tace-inhibitors |
| 02/08/2006 | EP1622612A1 Pharmaceutical formulation of the sodium salt of telmisartan |
| 02/08/2006 | EP1622604A1 Bicalutamide forms, compositions, and processes thereof |
| 02/08/2006 | EP1622603A2 Phenolic acid salts of gabapentin in solid dosage forms and methods of use |
| 02/08/2006 | EP1622601A1 Pharmaceutical compositions |
| 02/08/2006 | EP1622600A1 Pharmaceutical formulation comprising anti-obesity agent and acidulant |
| 02/08/2006 | EP1622595A1 Fast dissolving orally consumable films containing a modified starch for improved heat and moisture resistance |
| 02/08/2006 | EP1622594A2 Homogeneous, thermoreversible alginate films and soft capsules made therefrom |
| 02/08/2006 | EP1622593A1 Confectionery products for delivery of pharmaceutically active agents to the throat |
| 02/08/2006 | EP1622592A2 Implantable medication delivery device using pressure regulator |
| 02/08/2006 | EP1622591A1 Biphasic release of glipizide from monocompartment osmotic dosage form |
| 02/08/2006 | EP1622590A2 Novel composition for hormonal balance and uses thereof |
| 02/08/2006 | EP1622589A1 Compositions, targets, methods and devices for the therapy of ocular and periocular disorders |
| 02/08/2006 | EP1622588A2 Delivery systems of homogeneous thermoreversible alginate films |
| 02/08/2006 | EP1622587A1 Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts |
| 02/08/2006 | EP1622586A2 Process for preparing tannate tablet capsule or other solid dosage forms |
| 02/08/2006 | EP1622585A2 Lipid platinum complexes and methods of use thereof |
| 02/08/2006 | EP1622584A1 Pharmaceutical effervescent formulation comprising amoxycillin and clavulanic acid |
| 02/08/2006 | EP1622573A2 Molecules enhancing dermal delivery of influenza vaccines |
| 02/08/2006 | EP1622554A1 Compositions containing a combination of a pharmaceutical agent or a cosmetic agent and an oxy group-bearing aromatic aldehyde |
| 02/08/2006 | EP1622540A2 Formulations for cell- schedule dependent anticancer agents |
| 02/08/2006 | EP1622448A2 Nasal administration of the lh-rh analog leuprolide |
| 02/08/2006 | EP1599212A4 Combination therapy for the treatment of immunoinflammatory disorders |
| 02/08/2006 | EP1455750B1 Viscoelastic ophthalmic compositions comprising hyaluronic acid and chondroitin sulphate |
| 02/08/2006 | EP1453517B1 Platinum derivative pharmaceutical formulations |
| 02/08/2006 | EP1337262A4 Improved ophthalmic and contact lens solutions with a peroxide source and a cationic polymeric preservative |
| 02/08/2006 | EP1333858B1 Vaccines with enhanced immune response and methods for their preparation |
| 02/08/2006 | EP1331902A4 Improved ophthalmic and contact lens solutions containing forms of vitamin b |
| 02/08/2006 | EP1289642B1 Nanocapsules having a polyelectrolyte envelope |
| 02/08/2006 | EP1216035B1 Preparation containing active ingredients and/or auxiliary agents with a controlled release of these substances and the use and production of the same |
| 02/08/2006 | EP0736041B1 Transparent liquid for encapsulated drug delivery |
| 02/08/2006 | CN1732212A Multi-arm polypeptide-poly (ethylene glycol) block copolymers as drug delivery vehicles |
| 02/08/2006 | CN1732151A 4-nitro-2-[(4'-methoxyl)-phenoxy]-toluenesulfonamide derivant and its medical uses |
| 02/08/2006 | CN1732038A Emulsions including surface-modified organic molecules |
| 02/08/2006 | CN1732012A Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
| 02/08/2006 | CN1732008A Use of rimexolone in the treatment of dry eye |
| 02/08/2006 | CN1731995A Device for the transdermal administration of a rotigotine base. |
| 02/08/2006 | CN1731990A Nutritional composition for oral use |
| 02/08/2006 | CN1731988A Sustained release pharmaceutical composition |
| 02/08/2006 | CN1731987A Dosage form providing ascending release of liquid formulation |
| 02/08/2006 | CN1731986A Method for preparing PIT emulsion rubberized active fat soluble substance and emulsion prepared by the method |
| 02/08/2006 | CN1731985A Sustained release l-arginine formulations and methods of manufacture and use |
| 02/08/2006 | CN1731984A Drug particles obtained by freezing onto a cold surface |
| 02/08/2006 | CN1731983A Microcapsules having multiple shells and method for the preparation thereof |
| 02/08/2006 | CN1731982A Method of treating insulin resistance, adult onset diabetes and metabolic syndrome X |
| 02/08/2006 | CN1731981A Liposomal glucocorticoids |
| 02/08/2006 | CN1731980A Emulsions including surface-modified inorganic nanoparticles |
| 02/08/2006 | CN1731979A Allergen dosage form |